Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment

Michael H. Gold; Mark Lebwohl; Brian S. Biesman; Deanne Mraz Robinson; Lei Luo; David R. Berk; Gurpreet Ahluwalia; Nancy Alvandi

doi:10.1016/j.jaad.2018.05.037

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment

Michael H. Gold
, Mark Lebwohl
, Brian S. Biesman
, Deanne Mraz Robinson
, Lei Luo
, David R. Berk
, Gurpreet Ahluwalia
, Nancy Alvandi

Research output: Contribution to journal › Letter › peer-review

8 Scopus citations

Original language	English
Pages (from-to)	e57-e59
Journal	Journal of the American Academy of Dermatology
Volume	79
Issue number	3
DOIs	https://doi.org/10.1016/j.jaad.2018.05.037
State	Published - Sep 2018

Access to Document

10.1016/j.jaad.2018.05.037

Cite this

Gold, M. H., Lebwohl, M., Biesman, B. S., Robinson, D. M., Luo, L., Berk, D. R., Ahluwalia, G., & Alvandi, N. (2018). Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment. Journal of the American Academy of Dermatology, 79(3), e57-e59. https://doi.org/10.1016/j.jaad.2018.05.037

@article{4f98a20cd9be4fec971d0ab25a954881,

title = "Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment",

author = "Gold, \{Michael H.\} and Mark Lebwohl and Biesman, \{Brian S.\} and Robinson, \{Deanne Mraz\} and Lei Luo and Berk, \{David R.\} and Gurpreet Ahluwalia and Nancy Alvandi",

note = "Funding Information: Funding sources: Supported by Allergan plc, Dublin, Ireland. Writing and editorial assistance was also funded by Allergan plc. Neither honoraria nor other form of payments were made for authorship. ",

year = "2018",

month = sep,

doi = "10.1016/j.jaad.2018.05.037",

language = "English",

volume = "79",

pages = "e57--e59",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment

AU - Gold, Michael H.

AU - Lebwohl, Mark

AU - Biesman, Brian S.

AU - Robinson, Deanne Mraz

AU - Luo, Lei

AU - Berk, David R.

AU - Ahluwalia, Gurpreet

AU - Alvandi, Nancy

N1 - Funding Information: Funding sources: Supported by Allergan plc, Dublin, Ireland. Writing and editorial assistance was also funded by Allergan plc. Neither honoraria nor other form of payments were made for authorship.

PY - 2018/9

Y1 - 2018/9

UR - https://www.scopus.com/pages/publications/85051411966

U2 - 10.1016/j.jaad.2018.05.037

DO - 10.1016/j.jaad.2018.05.037

M3 - Letter

C2 - 29860043

AN - SCOPUS:85051411966

SN - 0190-9622

VL - 79

SP - e57-e59

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 3

ER -